|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/17 | |
| A61K 31/52 | |||
| A61K 39/395 | |||
| A61P 35/00 | |||
| A61K 45/06 |
| (11) | Patento numeris | 2350641 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09814951.1 |
| Europos patento paraiškos padavimo data | 2009-08-05 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-08-03 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-09-24 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2009/052789 |
| Data | 2009-08-05 |
| (87) | Numeris | WO 2010/033315 |
| Data | 2010-03-25 |
| (30) | Numeris | Data | Šalis |
| 99088 P | 2008-09-22 | US |
| (72) |
HOLLAND, Pamela, M., US
PIASECKI, Julia, C., US
BENETATOS, Christopher, A., US
CHUNDURU, Srinivas, K., US
MCKINLAY, Mark, A., US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive M/S 28-2-C, Thousand Oaks, CA 91320-1799,
US
Tetralogic Pharmaceuticals Corporation, 343 Phoenixville Pike, Malvern, PA 19355, US |
| (54) | A COMBINATION OF A TNF ALPHA INHIBITOR, AN IAP INHIBITOR AND A TRAIL RECEPTOR AGONIST FOR USE IN TREATING CANCER |
| A COMBINATION OF A TNF ALPHA INHIBITOR, AN IAP INHIBITOR AND A TRAIL RECEPTOR AGONIST FOR USE IN TREATING CANCER |